Top ▲
« Hide
More detailed introduction
This family contains agents that are able to modulate the regulatory mechanisms that control the immune responses of antigen-specific T cells, including those that are approved immunotherapeutics.
abatacept
Show summary »
More detailed page |
belatacept
Show summary »
More detailed page |
lulizumab pegol
Show summary »
More detailed page |
relatlimab
Show summary »
More detailed page |
ipilimumab
Show summary »
More detailed page |
pembrolizumab
Show summary »
More detailed page |
tremelimumab
Show summary »
More detailed page |
tislelizumab
Show summary »
More detailed page |
nivolumab
Show summary »
More detailed page |
moxetumomab pasudotox
Show summary »
More detailed page |
lintuzumab
Show summary »
More detailed page |
vadastuximab talirine
Show summary »
More detailed page |
gemtuzumab ozogamicin
Show summary »
More detailed page |
PD-L1 (programmed cell death 1 ligand 1) {Sp: Human}
Show summary »
More detailed page |
inotuzumab ozogamicin
Show summary »
More detailed page |
cemiplimab
Show summary »
More detailed page |
retifanlimab
Show summary »
More detailed page |
feladilimab
Show summary »
More detailed page |
Database page citation:
Immune checkpoint modulators. Accessed on 23/03/2023. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=969.